Form 4: Aktis Oncology Director Sells Shares
Insider Transaction (Form 4)
Ken Herrmann, a Director of Aktis Oncology, Inc., sold 3,065 shares of common stock on July 17, 2026 for $25.21 per share.
Summary
- Option exercise/conversion: acquired 3,065 Common Stock at $0.08 ($245) on July 17, 2026; holds 3,065 after (Direct).
- Open-market sale: disposed of 3,065 Common Stock at $25.21 ($77,259) on July 17, 2026 (Direct).
- Option exercise/conversion: disposed of 3,065 Stock Option (Right to Buy) on July 17, 2026; holds 3,506 after (Direct).
Sentiment
Score: 4
Explanation: StockSavvy.ai views this as a mildly negative signal: an insider sold $77,259 of stock on the open market.
Insider Transactions
Ken Herrmann — Director
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-07-17 | Option exercise/conversion | Common Stock | 3,065 | $0 | $245 | 3,065 |
| 2026-07-17 | Open-market sale | Common Stock | 3,065 | $25 | $77.3K | 0 |
| 2026-07-17 | Option exercise/conversion | Stock Option (Right to Buy) | 3,065 | — | — | 3,506 |
Key Dates
| Date | Description |
|---|---|
| 2026-07-17 | Option exercise/conversion (3,065 shares) |
| 2026-07-17 | Open-market sale (3,065 shares) |
| 2026-07-17 | Option exercise/conversion (3,065 shares) |
Keywords
insider transaction, Form 4, AKTS, Aktis Oncology, Inc., bearish, Ken Herrmann
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.